| |
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
September 4, 2013
North America plans will utilize social media strategies including calls to action for arrhythmia screening in sports
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it has engaged The Lightning Group (“TLG”) and LOLA Social Marketing (“LOLA”) to provide on-line marketing and social media strategy services. In exchange for these services, CardioComm Solutions has agreed to pay an aggregate of $25,000 in cash and to issue an aggregate of 175,979 common shares of the Company, representing $25,000 worth of shares. The number of shares to be issued is based on the closing price of the Company’s shares on the dates on which the service-milestones were met. The services agreement was previously disclosed by the Company in a press release dated March 8, 2013. When issued, the shares will be subject to a four month hold period. The issuance of the shares is subject to approval by the TSX Venture Exchange.
“TLG & LOLA teams are pleased to have assisted CardioComm Solutions in creating a novel ‘go to market’ strategy with respect to the introduction of the HeartCheckTM PEN devices and SMART Monitoring services into alternative health related distribution verticals including the nutrition, sports and alternative medicine markets,” said Howard Lichtman, President of The Lightning Group and former Executive VP of Marketing and Communications for Cineplex.
TLG develops innovative and effective strategies to oversee the design and implementation of new revenue optimization strategies. With extensive experience working at senior levels in blue chip companies across North America, TLG brings three unique advantages to its clients: design of imaginative business solutions that achieve quantifiable results; organization of a team of experts from virtually any fields to implement business solutions; and a valuable rolodex enabling facilitated entry into corporate America’s business.
“The HeartCheckTM Partner Program will help us create a large pool of advocates and supporters that are empowered to drive sales,” stated Luis Vieira, President of LOLA, Toronto. LOLA is a pure-play social media agency that uses proprietary social media listening tools to uncover business insights and drive strategies that lead to meaningful returns on a company’s investment in social media.
“With assistance from TLG and LOLA, a Partnership Program is being developed which creates an incentive for health-related professionals to purchase the HeartCheckTM PEN devices and utilize the SMART Monitoring service. Our recent update to the GEMS Home software will meet the new requirements for the Partner Program. Further, with TLG/LOLA advanced social media tools, we are targeting the growing demand for proactive screening of arrhythmias in athletes in the hope of stemming the increasing incidents of sudden cardiac related events as they have been appearing in the media on a regular basis,” said Etienne Grima, Chief Executive Officer of CardioComm Solutions. “The HeartCheckTM Partner Program is also being evaluated in the pharmacy setting to be used as a screening tool in conjunction with the prescription of medications that increase the risk for sudden cardiac death, a service that will provide consumers the benefit of regularly scheduled, rapid reporting and cost effective ECG readings.”
The HeartCheckTM PEN ECG device and associated GEMS Home software is the only FDA and Health Canada cleared over the counter (OTC) medical monitoring device that is permitted to show a person their own heart electrocardiogram (ECG) without a physician prescription. Under the proposed Partner Program, non-medical health practitioners such as fitness trainers, sports therapists, pharmacist, naturopaths and chiropractors may offer SMART Monitoring physician interpretations to their clients using a Partner version of GEMS Home. These Partner Program participants would offer their clients ECG readings for a fixed fee without the need for purchasing a HeartCheckTM PEN ECG device. The HeartCheckTM Partner will upload the readings through the Company’s patent pending, SMART Monitoring service to receive back a Physician ECG interpretation report in an average time of 30 minutes.
More information regarding the HeartCheckTM products and SMART Monitoring solution is available at the Company’s website www.theheartcheck.com. Partner Program updates will be available upon request.
About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
|
|
